Doximity (DOCS) Stock Forecast & Price Target

Compare

922 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DOCS Analyst Ratings

Moderate Buy

8 Buy

5 Hold

2 Sell

Based on 15 analysts giving stock ratings to

Doximity

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DOCS Stock 12 Month Forecast

Average Price Target

$66.62

▲(52.48% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Doximity in the last 3 months. The average price target is $66.62 with a high forecast of $82.00 and a low forecast of $55.00. The average price target represents a 52.48% change from the last price of $43.69.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"50":"$50","83":"$83","58.25":"$58.3","66.5":"$66.5","74.75":"$74.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$82.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66.62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$66.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$55.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[50,58.25,66.5,74.75,83],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.07,53.449230769230766,55.82846153846154,58.207692307692305,60.58692307692308,62.966153846153844,65.34538461538462,67.72461538461539,70.10384615384615,72.48307692307692,74.8623076923077,77.24153846153845,79.62076923076923,{"y":82,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.07,52.26615384615385,53.4623076923077,54.65846153846154,55.854615384615386,57.050769230769234,58.24692307692308,59.44307692307693,60.63923076923077,61.83538461538462,63.03153846153847,64.22769230769231,65.42384615384616,{"y":66.62,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.07,51.37230769230769,51.674615384615386,51.97692307692308,52.27923076923077,52.581538461538464,52.88384615384616,53.18615384615384,53.488461538461536,53.79076923076923,54.09307692307692,54.395384615384614,54.69769230769231,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.41,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.39,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.38,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$82.00

Average Price Target$66.62

Lowest Price Target$55.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Allen Lutz

Bank of America Securities

$82

Buy

87.69%

Upside

Reiterated

12/16/25

Doximity Positioned for Growth: Buy Rating Backed by Rising HCP Budgets and Digital Video Initiatives

Craig Hettenbach

Morgan Stanley

$62→$65

Buy

48.78%

Upside

Upgraded

12/15/25

Analysts Offer Insights on Healthcare Companies: Doximity (NYSE: DOCS), Cogstate Ltd (Other OTC: COGZF) and Sanofi (Other OTC: SNYNF)

Jailendra Singh

Truist Financial

Hold

―

Reiterated

12/15/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Caris Life Sciences, Inc. (NASDAQ: CAI) and Doximity (NYSE: DOCS)

Glen Santangelo

Barclays

$63

Buy

44.20%

Upside

Initiated

12/08/25

Doximity initiated with an Overweight at BarclaysDoximity initiated with an Overweight at Barclays

Elizabeth Anderson CFA

Evercore ISI

$70

Buy

60.22%

Upside

Reiterated

12/08/25

Doximity (DOCS) Gets a Buy from Evercore ISI

Brian Peterson

Raymond James

$75→$65

Buy

48.78%

Upside

Reiterated

11/21/25

Doximity: Strong Growth Potential and Attractive Valuation Amid Share Price Pullback

Sean Dodge

BMO Capital

$55

Hold

25.89%

Upside

Initiated

11/12/25

Doximity initiated with a Market Perform at BMO CapitalDoximity initiated with a Market Perform at BMO Capital

Richard Close

Canaccord Genuity

$67→$58

Hold

32.75%

Upside

Reiterated

11/10/25

Doximity price target lowered to $58 from $67 at CanaccordDoximity price target lowered to $58 from $67 at Canaccord

Steven Valiquette

Mizuho Securities

$60→$62

Hold

41.91%

Upside

Reiterated

11/10/25

Doximity price target raised to $62 from $60 at MizuhoDoximity price target raised to $62 from $60 at Mizuho

Ryan Daniels

William Blair

Buy

―

Reiterated

11/07/25

Doximity's Strong Financial Performance and Strategic Positioning Justify Buy Rating

Ryan MacDonald

Needham

$75

Buy

71.66%

Upside

Reiterated

11/07/25

Doximity (DOCS) Gets a Buy from Needham

Stan Berenshteyn

Wells Fargo

$65

Hold

48.78%

Upside

Assigned

11/06/25

Doximity's Hold Rating: Balancing Short-Term Gains with Long-Term Uncertainty Amid Competitive Pressures

Alexei Gogolev

J.P. Morgan

$62

Sell

41.91%

Upside

Downgraded

10/14/25

Doximity (DOCS) was downgraded to a Sell Rating at J.P. Morgan

Scott Schoenhaus

KeyBanc

$75→$80

Buy

83.11%

Upside

Reiterated

10/08/25

Doximity price target raised to $80 from $75 at KeyBancDoximity price target raised to $80 from $75 at KeyBanc

David Roman

Goldman Sachs

$57→$64

Sell

46.49%

Upside

Downgraded

10/01/25

Doximity downgraded to Sell from Neutral at Goldman SachsDoximity downgraded to Sell from Neutral at Goldman Sachs

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Allen Lutz

Bank of America Securities

$82

Buy

87.69%

Upside

Reiterated

12/16/25

Doximity Positioned for Growth: Buy Rating Backed by Rising HCP Budgets and Digital Video Initiatives

Craig Hettenbach

Morgan Stanley

$62→$65

Buy

48.78%

Upside

Upgraded

12/15/25

Analysts Offer Insights on Healthcare Companies: Doximity (NYSE: DOCS), Cogstate Ltd (Other OTC: COGZF) and Sanofi (Other OTC: SNYNF)

Jailendra Singh

Truist Financial

Hold

―

Reiterated

12/15/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Caris Life Sciences, Inc. (NASDAQ: CAI) and Doximity (NYSE: DOCS)

Glen Santangelo

Barclays

$63

Buy

44.20%

Upside

Initiated

12/08/25

Doximity initiated with an Overweight at BarclaysDoximity initiated with an Overweight at Barclays

Elizabeth Anderson CFA

Evercore ISI

$70

Buy

60.22%

Upside

Reiterated

12/08/25

Doximity (DOCS) Gets a Buy from Evercore ISI

Brian Peterson

Raymond James

$75→$65

Buy

48.78%

Upside

Reiterated

11/21/25

Doximity: Strong Growth Potential and Attractive Valuation Amid Share Price Pullback

Sean Dodge

BMO Capital

$55

Hold

25.89%

Upside

Initiated

11/12/25

Doximity initiated with a Market Perform at BMO CapitalDoximity initiated with a Market Perform at BMO Capital

Richard Close

Canaccord Genuity

$67→$58

Hold

32.75%

Upside

Reiterated

11/10/25

Doximity price target lowered to $58 from $67 at CanaccordDoximity price target lowered to $58 from $67 at Canaccord

Steven Valiquette

Mizuho Securities

$60→$62

Hold

41.91%

Upside

Reiterated

11/10/25

Doximity price target raised to $62 from $60 at MizuhoDoximity price target raised to $62 from $60 at Mizuho

Ryan Daniels

William Blair

Buy

―

Reiterated

11/07/25

Doximity's Strong Financial Performance and Strategic Positioning Justify Buy Rating

Ryan MacDonald

Needham

$75

Buy

71.66%

Upside

Reiterated

11/07/25

Doximity (DOCS) Gets a Buy from Needham

Stan Berenshteyn

Wells Fargo

$65

Hold

48.78%

Upside

Assigned

11/06/25

Doximity's Hold Rating: Balancing Short-Term Gains with Long-Term Uncertainty Amid Competitive Pressures

Alexei Gogolev

J.P. Morgan

$62

Sell

41.91%

Upside

Downgraded

10/14/25

Doximity (DOCS) was downgraded to a Sell Rating at J.P. Morgan

Scott Schoenhaus

KeyBanc

$75→$80

Buy

83.11%

Upside

Reiterated

10/08/25

Doximity price target raised to $80 from $75 at KeyBancDoximity price target raised to $80 from $75 at KeyBanc

David Roman

Goldman Sachs

$57→$64

Sell

46.49%

Upside

Downgraded

10/01/25

Doximity downgraded to Sell from Neutral at Goldman SachsDoximity downgraded to Sell from Neutral at Goldman Sachs

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Doximity

1 Month

xxx

Success Rate

6/11 ratings generated profit

Average Return

-2.25%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of -2.25% per trade.

3 Months

xxx

Success Rate

7/11 ratings generated profit

Average Return

+3.80%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +3.80% per trade.

1 Year

Allen LutzBank of America Securities

Success Rate

6/11 ratings generated profit

Average Return

-1.98%

reiterated a buy rating 13 days ago

Copying Allen Lutz's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of -1.98% per trade.

2 Years

xxx

Success Rate

9/19 ratings generated profit

Average Return

+14.19%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 47.37% of your transactions generating a profit, with an average return of +14.19% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DOCS Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DOCS has received 18 Buy Ratings, 10 Hold Ratings, and 3 Sell Ratings. DOCS average Analyst price target in the past 3 months is 66.62.

Each month's total comprises the sum of three months' worth of ratings.

DOCS Financial Forecast

DOCS Earnings Forecast

Next quarter’s earnings estimate for DOCS is $0.45 with a range of $0.37 to $0.48. The previous quarter’s EPS was $0.45. DOCS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year DOCS has Performed in-line its overall industry.

DOCS Sales Forecast

Next quarter’s sales forecast for DOCS is $181.97M with a range of $180.30M to $192.21M. The previous quarter’s sales results were $168.53M. DOCS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year DOCS has Performed in-line its overall industry.

DOCS Stock Forecast FAQ

What is DOCS’s average 12-month price target, according to analysts?

Based on analyst ratings, Doximity, Inc.’s 12-month average price target is 66.62.

What is DOCS’s upside potential, based on the analysts’ average price target?

Doximity, Inc. has 52.48% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DOCS a Buy, Sell or Hold?

Doximity, Inc. has a consensus rating of Moderate Buy which is based on 8 buy ratings, 5 hold ratings and 2 sell ratings.

What is Doximity, Inc.’s price target?

The average price target for Doximity, Inc. is 66.62. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $82.00 ,the lowest forecast is $55.00. The average price target represents 52.48% Increase from the current price of $43.69.

What do analysts say about Doximity, Inc.?

Doximity, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of DOCS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Doximity (DOCS) Stock Forecast & Price Target

DOCS Analyst Ratings

DOCS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Doximity

DOCS Analyst Recommendation Trends

DOCS Financial Forecast

DOCS Earnings Forecast

DOCS Sales Forecast

DOCS Stock Forecast FAQ

Detailed List of Analyst Forecasts